StageAsset Sale | AssetsPurchased
About Acylin Therapeutics
Aylin Therapeutics is a biotechnology company focused on developing inhibitors of cellular acylation, an enzymatic mechanism fundamental to the molecular pathology of cancer, metabolic disease, and neurodegeneration. The Company has developed a platform technology to design specific acyltransferase inhibitors based on crystal structures, novel medicinal chemical approaches, and mechanistic understanding of biological and chemical pathways.
Missing: Acylin Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Acylin Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Acylin Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Acylin Therapeutics is included in 1 Expert Collection, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Acylin Therapeutics Frequently Asked Questions (FAQ)
Where is Acylin Therapeutics's headquarters?
Acylin Therapeutics's headquarters is located at 1616 EastLake Avenue, Seattle.
What is Acylin Therapeutics's latest funding round?
Acylin Therapeutics's latest funding round is Asset Sale.
How much did Acylin Therapeutics raise?
Acylin Therapeutics raised a total of $4M.
Who are the investors of Acylin Therapeutics?
Investors of Acylin Therapeutics include ARCH Venture Partners, WRF Capital, OVP Venture Partners, Amgen Ventures, PPD and 5 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.